OraSure Technologies Praises New Hepatitis C Testing Recommendations by U.S. Preventive Services Task Force

OraSure Technologies Praises New Hepatitis C Testing Recommendations by U.S.
Preventive Services Task Force

New Recommendations Advocate Testing for Both At-Risk Individuals and All
Individuals Born Between 1945 and 1965

BETHLEHEM, Pa., June 25, 2013 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc.
(Nasdaq:OSUR) announced today its support for the new recommendations issued
today by the U.S. Preventive Services Task Force (USPSTF), giving both
hepatitis C (HCV) screening for at-risk individuals and age-cohort screening a
'B' grade. Under the Affordable Care Act, preventive services that have
received an 'A' or 'B' grade from the USPSTF must be covered by insurance
policies without cost-sharing and be part of the essential health benefits for
those individuals eligible for Medicare.

The new recommendations, entitled "Screening for Hepatitis C Virus Infection
in Adults: U.S. Preventive Services Task Force Recommendation Statement," are
a significant expansion of the USPSTF's previous recommendation of screening
for HCV. This new recommendation is in response to the higher prevalence of
HCV infection in Baby Boomers (those born between 1945 and 1965),
approximately 80 million individuals. The Centers for Disease Control and
Prevention (CDC) estimates that one out of every 30 Baby Boomers is living
with hepatitis C infection. The USPSTF is recommending that all Baby Boomers
be tested for hepatitis C at least once.

According to the CDC, the hepatitis C virus infection is the most common
chronic blood-borne infection in the United States. Up to 75 percent of people
with hepatitis C are unaware of their infection. Hepatitis C is the leading
cause of liver cancer and liver transplants in the United States. If left
undetected and untreated, the total medical costs for patients with HCV are
expected to nearly triple over the next 20 years – from $30 billion to $85
billion according to the Millman Report entitled "Consequences of Hepatitis C
Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease."

"We applaud the new U.S. Preventive Services Task Force recommendations, which
will help to make hepatitis C screening much more accessible as a regular part
of medical care," said Douglas A. Michels, President and Chief Executive
Officer of OraSure Technologies. "As a result of the recommendations, we
believe that over time more individuals will get tested and learn their
hepatitis C status, and we expect that our OraQuick® Rapid HCV test will
enable individuals presumed to be infected to be referred immediately for
follow-up care."

The OraQuick® HCV Rapid Antibody Test is the first and only FDA-approved,
CLIA-waived rapid, point-of-care test for the detection of antibodies to the
hepatitis C virus. OraQuick® HCV results are available in 20 minutes, which
can help increase the delivery of test results, allowing early diagnosis and
linkage to care, treatment and prevention services, particularly for those at
risk for hepatitis C.

The USPSTF is an independent group of national experts in prevention and
evidence-based medicine that works to improve the health of all Americans by
making evidence-based recommendations about clinical preventive services such
as screenings, counseling services, and preventive medications. USPSTF
recommendations have formed the basis of the clinical standards for many
professional societies, health organizations, and medical quality review
groups.

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and
distribution of oral fluid diagnostic and collection devices and other
technologies designed to detect or diagnose critical medical conditions. Its
innovative products include rapid tests for the detection of antibodies to HIV
and HCV at the point of care and testing solutions for detecting various drugs
of abuse. In July 2012, the Company received approval from the U.S. Food and
Drug Administration for the Company's OraQuick® In-Home HIV Test for sale
directly to consumers in the over-the-counter (OTC) market - making it the
first and only rapid OTC HIV test approved in the U.S. In addition, the
Company is a leading provider of oral fluid sample collection, stabilization
and preparation products for molecular diagnostic applications. OraSure's
portfolio of products is sold globally to various clinical laboratories,
hospitals, clinics, community-based organizations and other public health
organizations, research and academic institutions, distributors, government
agencies, physicians' offices, and commercial and industrial entities. The
Company's products enable healthcare providers to deliver critical information
to patients, empowering them to make decisions to improve and protect their
health.

For more information on OraSure Technologies, please visit www.orasure.com.

CONTACT: Media Contact:
         Jennifer Moritz
         Zer0 to 5ive for OraSure Technologies
         917-748-4006
         jmoritz@0to5.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.